Dinic J, Podolski-Renic A, Novakovic M, Li L, Opsenica I, Pesic M
Molecules. 2024; 29(18).
PMID: 39339303
PMC: 11433820.
DOI: 10.3390/molecules29184308.
Wang Y, Tu M, Yu A
Front Pharmacol. 2024; 15:1423416.
PMID: 39114355
PMC: 11303158.
DOI: 10.3389/fphar.2024.1423416.
Sun X, Chen J, Chen X, Gao Q, Chen W, Zou X
Dis Markers. 2022; 2022:1360954.
PMID: 36051356
PMC: 9427288.
DOI: 10.1155/2022/1360954.
Ahmed Juvale I, Abdul Hamid A, Abd Halim K, Che Has A
Heliyon. 2022; 8(6):e09777.
PMID: 35789865
PMC: 9249865.
DOI: 10.1016/j.heliyon.2022.e09777.
Szczepanek J, Skorupa M, Tretyn A
Cells. 2022; 11(6).
PMID: 35326459
PMC: 8947269.
DOI: 10.3390/cells11061008.
The Roles of microRNAs in Cancer Multidrug Resistance.
Pavlikova L, Seres M, Breier A, Sulova Z
Cancers (Basel). 2022; 14(4).
PMID: 35205839
PMC: 8870231.
DOI: 10.3390/cancers14041090.
MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets.
Marima R, Francies F, Hull R, Molefi T, Oyomno M, Khanyile R
Biomedicines. 2021; 9(12).
PMID: 34944633
PMC: 8698559.
DOI: 10.3390/biomedicines9121818.
MicroRNAs as a clue to overcome breast cancer treatment resistance.
Garrido-Cano I, Pattanayak B, Adam-Artigues A, Lameirinhas A, Torres-Ruiz S, Tormo E
Cancer Metastasis Rev. 2021; 41(1):77-105.
PMID: 34524579
PMC: 8924146.
DOI: 10.1007/s10555-021-09992-0.
Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients.
Dai H, Sheng X, Sha R, Peng J, Yang F, Zhou L
Front Oncol. 2021; 11:604319.
PMID: 33738251
PMC: 7961084.
DOI: 10.3389/fonc.2021.604319.
miR-137: A Novel Therapeutic Target for Human Glioma.
Wang Y, Chen R, Zhou X, Guo R, Yin J, Li Y
Mol Ther Nucleic Acids. 2020; 21:614-622.
PMID: 32736290
PMC: 7393316.
DOI: 10.1016/j.omtn.2020.06.028.
miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4.
Du F, Yu L, Wu Y, Wang S, Yao J, Zheng X
Cell Death Dis. 2019; 10(12):922.
PMID: 31801953
PMC: 6892819.
DOI: 10.1038/s41419-019-2164-2.
Efficient Delivery of MicroRNA and AntimiRNA Molecules Using an Argininocalix[4]arene Macrocycle.
Gasparello J, Lomazzi M, Papi C, DAversa E, Sansone F, Casnati A
Mol Ther Nucleic Acids. 2019; 18:748-763.
PMID: 31733592
PMC: 6859282.
DOI: 10.1016/j.omtn.2019.09.029.
miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells.
Xu X, Chen X, Xu M, Liu X, Pan B, Qin J
Aging (Albany NY). 2019; 11(18):7357-7385.
PMID: 31543507
PMC: 6781994.
DOI: 10.18632/aging.102214.
Differential microRNA expression profiles determined by next-generation sequencing in three fulvestrant-resistant human breast cancer cell lines.
Guo J, He K, Zeng H, Shi Y, Ye P, Zhou Q
Oncol Lett. 2019; 17(4):3765-3776.
PMID: 30930984
PMC: 6425361.
DOI: 10.3892/ol.2019.10061.
The role and mechanisms of action of microRNAs in cancer drug resistance.
Si W, Shen J, Zheng H, Fan W
Clin Epigenetics. 2019; 11(1):25.
PMID: 30744689
PMC: 6371621.
DOI: 10.1186/s13148-018-0587-8.
MDR1 in immunity: friend or foe?.
Bossennec M, Di Roio A, Caux C, Menetrier-Caux C
Oncoimmunology. 2018; 7(12):e1499388.
PMID: 30524890
PMC: 6279327.
DOI: 10.1080/2162402X.2018.1499388.
FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation.
Cheng S, Huang Y, Lou C, He Y, Zhang Y, Zhang Q
Cancer Biol Ther. 2018; 20(3):328-337.
PMID: 30336071
PMC: 6370380.
DOI: 10.1080/15384047.2018.1529101.
Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.
Chu P, Lin P, Wu H, Lin K, Wu C, Bekaii-Saab T
Oncogene. 2018; 37(25):3440-3455.
PMID: 29559746
DOI: 10.1038/s41388-018-0222-3.
Comparative Aspects of Molecular Mechanisms of Drug Resistance through ABC Transporters and Other Related Molecules in Canine Lymphoma.
Tomiyasu H, Tsujimoto H
Vet Sci. 2017; 2(3):185-205.
PMID: 29061940
PMC: 5644633.
DOI: 10.3390/vetsci2030185.
Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-κB signaling pathway in human neuroblastoma SH-SY5Y cells.
Wang H, Sun R, Chi Z, Li S, Hao L
Mol Cell Biochem. 2017; 433(1-2):1-12.
PMID: 28382490
DOI: 10.1007/s11010-017-3011-3.